Metastatic colorectal cancer Trials in Guangzhou, China
Conditions / Metastatic colorectal cancer / Guangzhou, China
Clinical trials for Metastatic colorectal cancer investigate a range of treatment strategies and patient populations.
32 total trials for this combination
Showing top 10 of 32 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00399035 | Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | COMPLETED | PHASE3 |
| NCT05004350 | A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | COMPLETED | — |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | COMPLETED | PHASE3 |
| NCT05652894 | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | RECRUITING | — |
| NCT02332499 | Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) | COMPLETED | PHASE2/PHASE3 |
| NCT05652894 | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | RECRUITING | — |
| NCT01103323 | Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy | COMPLETED | PHASE3 |
| NCT04008030 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | ACTIVE_NOT_RECRUITING | — |
| NCT05004350 | A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | COMPLETED | — |